GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
2013; Elsevier BV; Volume: 121; Issue: 25 Linguagem: Inglês
10.1182/blood-2012-10-460170
ISSN1528-0020
AutoresEric Padron, Jeffrey S. Painter, Sateesh Kunigal, Adam W. Mailloux, Kathy L. McGraw, Jessica M. McDaniel, Eun Hee Kim, Christopher Bebbington, Mark Baer, Geoffrey Yarranton, Jeffrey E. Lancet, Rami S. Komrokji, Omar Abdel‐Wahab, Alan F. List, Pearlie K. Epling‐Burnette,
Tópico(s)Eosinophilic Disorders and Syndromes
ResumoKey Points GM-CSF–dependent STAT5 hypersensitivity is detected in 90% of CMML samples and is enhanced by signaling mutations. Treatment with a GM-CSF–neutralizing antibody and JAK2 inhibitors reveals therapeutic potential.
Referência(s)